All Articles

The first off-the-shelf chimeric antigen receptor (CAR) T-cell platform targeting CD7 induced a complete response (CR) with no minimal residual disease (MRD) in 4 of the first 5 adults with adult relapsed/ refractory T-cell acute lymphoblastic leukemia (T-ALL) who were treated with the universal CAR T-cell therapy known as GC027.

The combination of the checkpoint inhibitor durvalumab, the PARP inhibitor olaparib, and the taxane paclitaxel as neoadjuvant therapy improved pathological complete response (pCR) compared with physician’s choice of chemotherapy in high-risk HER2-negative stage II or III breast cancer.

The combination of the checkpoint inhibitor atezolizumab plus the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib improved progression-free survival (PFS) and lengthened duration of responses compared with the 2 targeted therapies plus placebo in newly diagnosed BRAF V600E/K–mutant advanced melanoma, according to results of the phase 3 IMspire150 trial presented at the 2020 virtual meeting of the American Association for Cancer Research.

The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce the launch of a national committee addressing community outreach, prevention, and early detection.

The Academy of Oncology Nurse & Patient Navigators (AONN+) has heard from many of its members working on the front lines of cancer care about the impact of COVID-19 on their practice.

Who stands to benefit from lung cancer screening? Click here to find out.

In no arena is fear more relevant than in the realm of cancer survivorship. This article will help you to identify and address fear of recurrence for your patients.

Distress comes in many forms. Click here for strategies to identify and manage distress for your patients.